A Single Injection Restored Their Hearing — So Why Aren't Deaf Communities Celebrating?
An AAV-OTOF gene therapy trial restored hearing in all ten patients with congenital deafness, improving average thresholds from 106 dB to 52 dB, yet the breakthrough has ignited fierce opposition from Deaf communities who view it as an existential threat to their culture and identity. With FDA approval of Regeneron's DB-OTO imminent and China already leading the world with 21 treated patients, this medical milestone forces an uncomfortable reckoning: the collision between a genuine cure and the rights of a linguistic minority, compounded by deep inequities in global access and unresolved ethical questions about treating infants who cannot consent to irreversible changes in their biology.